MA34340B1 - Composes heteroaryles contenant de l'azote - Google Patents

Composes heteroaryles contenant de l'azote

Info

Publication number
MA34340B1
MA34340B1 MA35502A MA35502A MA34340B1 MA 34340 B1 MA34340 B1 MA 34340B1 MA 35502 A MA35502 A MA 35502A MA 35502 A MA35502 A MA 35502A MA 34340 B1 MA34340 B1 MA 34340B1
Authority
MA
Morocco
Prior art keywords
containing nitrogen
compounds containing
heteroaryl compounds
medicines
esters
Prior art date
Application number
MA35502A
Other languages
English (en)
Inventor
Konrad Bleicher
Alexander Flohr
Zbinden Katrin Groebke
Felix Gruber
Matthias Koerner
Bernd Kuhn
Jens-Uwe Peters
Sarmiento Rosa Maria Rodriguez
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34340B1 publication Critical patent/MA34340B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS HÉTÉROARYLES CONTENANT DE L'AZOTE DE FORMULE (I) OÙ A1, A2, (A), R1, R2, R3, R4, R5 ET R6 SONT COMME DÉFINI DANS LA DESCRIPTION ET DANS LES REVENDICATIONS, AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET LEURS ESTERS. CES COMPOSÉS INHIBENT PDE10A ET PEUVENT ÊTRE UTILISÉS COMME MÉDICAMENTS.
MA35502A 2010-06-09 2011-06-06 Composes heteroaryles contenant de l'azote MA34340B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10165427 2010-06-09
PCT/EP2011/059234 WO2011154327A1 (fr) 2010-06-09 2011-06-06 Composés hétéroaryles contenant de l'azote

Publications (1)

Publication Number Publication Date
MA34340B1 true MA34340B1 (fr) 2013-06-01

Family

ID=44483879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35502A MA34340B1 (fr) 2010-06-09 2011-06-06 Composes heteroaryles contenant de l'azote

Country Status (24)

Country Link
US (1) US8703768B2 (fr)
EP (1) EP2580207B1 (fr)
JP (1) JP5940523B2 (fr)
KR (1) KR101757959B1 (fr)
CN (1) CN102947292B (fr)
AR (1) AR081649A1 (fr)
BR (1) BR112012031343A2 (fr)
CA (1) CA2799022A1 (fr)
CL (1) CL2012003421A1 (fr)
CO (1) CO6620065A2 (fr)
CR (1) CR20120594A (fr)
EA (1) EA022075B1 (fr)
EC (1) ECSP12012330A (fr)
IL (1) IL223069A0 (fr)
MA (1) MA34340B1 (fr)
MX (1) MX2012013907A (fr)
NZ (1) NZ603230A (fr)
PE (1) PE20130279A1 (fr)
PH (1) PH12012502335A1 (fr)
SG (1) SG185655A1 (fr)
TW (1) TW201202221A (fr)
UA (1) UA108105C2 (fr)
WO (1) WO2011154327A1 (fr)
ZA (1) ZA201209119B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2739344A1 (fr) * 2008-10-14 2010-04-22 Actelion Pharmaceuticals Ltd Derives de phenethylamide et leurs analogues heterocycliques
JP6161537B2 (ja) 2010-04-07 2017-07-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法
CA2827724A1 (fr) 2011-02-18 2012-08-23 Allergan, Inc. Derives de 6,7-dialkoxy-3-isoquinolinol substitues en tant qu'inhibiteurs de la phosphodiesterase 10 (pde10a)
EP2760857A1 (fr) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Composés de type pyrazol-4-yl-hétérocyclyl-carboxamide et leurs méthodes d'utilisation
EP2712862A1 (fr) * 2012-09-28 2014-04-02 Splicos Nouveaux composés anti-invasifs
EP2903613B1 (fr) * 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Composés pyrazoliques utiles en tant qu'inhibiteurs d'activité d'irak4
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
NZ708593A (en) 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
RU2015147450A (ru) * 2013-04-29 2017-06-05 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ 2-ФЕНИЛ ИЛИ 2-ГЕТЕРОАРИЛ ИМИДАЗОЛ[1,2-a]ПИРИДИНА
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
US20160264536A1 (en) * 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US10420341B2 (en) * 2015-01-30 2019-09-24 Basf Se Herbicidal phenylpyrimidines
US9624246B2 (en) * 2015-02-06 2017-04-18 Merck Patent Gmbh Pyridazinone macrocycles as IRAK inhibitors and uses thereof
CN104610189A (zh) * 2015-02-10 2015-05-13 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构sglt2/sglt1双靶点抑制剂及用途
CN104974075A (zh) * 2015-08-07 2015-10-14 新秀化学（烟台）有限公司 一种n, n-二(2,2,6,6-四甲基-4-哌啶基) -1,3-苯二甲酰胺的制备方法
EP4302834A3 (fr) * 2016-07-12 2024-07-17 Revolution Medicines, Inc. 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu'inhibiteurs allostériques de shp2
BR112018077111A2 (pt) 2016-07-26 2019-04-02 Basf Se uso de compostos de pirimidina, compostos de pirimidina, mistura herbicida, composições herbicidas, método para controlar vegetação indesejada e uso das composições
EP3490381A1 (fr) 2016-07-27 2019-06-05 Basf Se Composés herbicides de pyrimidine
WO2018019767A1 (fr) 2016-07-27 2018-02-01 Basf Se Composés herbicides de pyridine
AU2017303138A1 (en) 2016-07-28 2019-01-03 Basf Se Herbicidal pyrimidine compounds
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての多環式化合物
WO2019121374A1 (fr) 2017-12-20 2019-06-27 Basf Se Composés herbicides de pyrimidine
WO2019121352A1 (fr) 2017-12-20 2019-06-27 Basf Se Composés herbicides de pyrimidine
BR112020012455B1 (pt) * 2017-12-20 2024-04-30 Pi Industries Ltd Pirazolopiridina-diamidas, seu uso como inseticida e processos para sua preparação
WO2020003244A2 (fr) 2018-06-29 2020-01-02 DePuy Synthes Products, Inc. Lame de scie hybride
CN112955443A (zh) 2018-09-19 2021-06-11 拜耳公司 具有除草活性的取代的苯基嘧啶酰肼
JP7288051B2 (ja) * 2018-11-02 2023-06-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害薬としての２－アミノ－Ｎ－ヘテロアリール－ニコチンアミド類
EP4052760B1 (fr) 2019-10-31 2024-03-13 FUJIFILM Corporation Dérivé de pyrazine ou sel de celui-ci et son utilisation
EP4190402B1 (fr) 2020-07-30 2025-08-27 FUJIFILM Corporation Composé hétérocyclique à teneur en azote ou sel de celui-ci, application de celui-ci, et intermédiaire de celui-ci
AU2021377248B2 (en) 2020-11-13 2025-12-18 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
EP4319872A4 (fr) * 2021-04-05 2025-03-12 Inipharm, Inc. Inhibiteurs d'hsd17b13 de type thiazole/isothiazole et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
EP1193261A1 (fr) 2000-10-02 2002-04-03 Warner-Lambert Company Thiadiazoles et leur utilisation comme inhibiteurs de phophodiestérase-7
EP1651251A4 (fr) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CA2555402A1 (fr) 2004-02-12 2005-09-01 Celine Bonnefous Amides bipyridyles en tant que modulateurs du recepteur-5 metabotropique du glutamate
WO2006094639A1 (fr) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Dérivés de pyridine-2-carboxamide en tant qu’antagonistes du mglur5
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
AR057987A1 (es) 2005-11-24 2008-01-09 Astrazeneca Ab Compuestos agonistas de cb1 (receptor cannabinoide)
CA2679659C (fr) 2007-03-01 2016-01-19 Novartis Ag Inhibiteurs de pim kinase et procedes de leur utilisation
WO2009026241A1 (fr) 2007-08-23 2009-02-26 Kalypsys, Inc. Modulateurs hétérocycliques de tgr5
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives

Also Published As

Publication number Publication date
US8703768B2 (en) 2014-04-22
SG185655A1 (en) 2012-12-28
US20110306589A1 (en) 2011-12-15
KR101757959B1 (ko) 2017-07-14
CL2012003421A1 (es) 2013-07-26
IL223069A0 (en) 2013-02-03
CO6620065A2 (es) 2013-02-15
BR112012031343A2 (pt) 2016-11-01
WO2011154327A1 (fr) 2011-12-15
JP2013528193A (ja) 2013-07-08
EA201291282A1 (ru) 2013-06-28
AR081649A1 (es) 2012-10-10
EP2580207A1 (fr) 2013-04-17
TW201202221A (en) 2012-01-16
JP5940523B2 (ja) 2016-06-29
CN102947292B (zh) 2015-08-19
NZ603230A (en) 2013-09-27
HK1178900A1 (en) 2013-09-19
PH12012502335A1 (en) 2013-02-11
CA2799022A1 (fr) 2011-12-15
EP2580207B1 (fr) 2017-09-27
ZA201209119B (en) 2015-05-27
MX2012013907A (es) 2012-12-17
ECSP12012330A (es) 2012-12-28
UA108105C2 (ru) 2015-03-25
EA022075B1 (ru) 2015-10-30
CR20120594A (es) 2013-01-03
PE20130279A1 (es) 2013-03-08
CN102947292A (zh) 2013-02-27
KR20130112858A (ko) 2013-10-14

Similar Documents

Publication Publication Date Title
MA34340B1 (fr) Composes heteroaryles contenant de l'azote
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
EA200971104A1 (ru) Производные бензимидазола
MA46452B1 (fr) Composés de benzo[b]thiophéne en tant qu'agonistes de sting
UA105229C2 (uk) Фармацевтичний склад
TW200612958A (en) Substituted imidazole derivatives
ECSP088871A (es) Derivados de triazolopirazina
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA30162B1 (fr) Nouveaux derives de pyrrole a cycles fusionnes
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
MA33330B1 (fr) Quinazolines substituées comme fongicides
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
MX2011012739A (es) Derivados fluorados de aminotriazol.
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA34008B1 (fr) Composes en tant qu'antagonistes de la bradykinine b1
UA103329C2 (ru) Соли соединений-ингибиторов вич
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
MA34946B1 (fr) Nouvelles benzodioxolepipérazines
FR2935394B1 (fr) Microorganismes photosynthetiques enrichis en selenium organique a partir de composes seleno-hydroxyacides et leurs applications en nutrition, cosmetique et pharmacie
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
MY147188A (en) Substituted imidazole compounds as ksp inhibitors